Plunkett Research Online: Atreca Inc

ATRECA INC (BCEL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Atreca, Inc. is a biopharmaceutical company utilizing its proprietary platform to discover and develop novel antibody-based immunotherapeutics to treat various types of solid tumors. Atreca’s lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target deriv.....



Atreca Inc
Ticker: BCEL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 595-2595
Fax: 650 453-2410
Address: 450 East Jamie Court
South San Francisco, CA 94080 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Biopharmaceuticals
Drug Discovery
Clinical Testing
Antibody Immunotherapeutics
Oncology
Contacts Description

John Orwin CEO/Director/President
Herbert Cross CFO
See More
Atreca, Inc. is a biopharmaceutical company utilizing its proprietary platform to discover and develop novel antibody-based immunotherapeutics to treat various types of solid tumors. Atreca’s lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target deriv.....See More See More

Auditor: OUM & Co. LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
ATRC-101
APN-122597
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: